［1］Baselga J，Campone M，Piccart M，et al.Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer［J］.N Engl J Med，2012，366(6)：520-529. 

［2］Yao JC，Shah MH，Ito T，et al.Everolimus for advanced pancreatic neuroendocrine tumors［J］.N Engl J Med，2011，364(6)：514-523. 

［3］Howell A，Robertson JF，Quaresma Albano J，et al.Fulvestrant，formerly ICI 182，780，is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment［J］.J Clin Oncol，2002，20(16)：3396-3403. 

［4］Osborne CK，Pippen J，Jones SE，et al.Double-blind，randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy：results of a North American trial［J］.J Clin Oncol，2002，20(16)：3386-3395. 

［5］Xu B，Jiang Z，Shao Z，et al.Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer：results of a multicentre，double-blind，randomised phase Ⅲ trial.Cancer Chemother Pharmacol［J］.2011，67(1)：223-230. 

［6］Bergh J，Jnsson PE，Lidbrink EK，et al.FACT：An Open-Label Randomized Phase Ⅲ Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone as First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer［J］.J Clin Oncol，2012［Epub ahead of print］

［7］Van de Steene J，Soete G，Storme G.Adjuvant radiotherapy for breast cancer significantly improves overall survival：the missing link.Radiother Oncol［J］.2000，55(3)：263-272. 

［8］Fowble B，Hanlon A，Freedman G，et al.Internal mammary node irradiation neither decreases distant metastases nor improves survival in stage Ⅰ and Ⅱ breast cancer［J］.Int J Radiat Oncol Biol Phys，2000，47(4)：883-894. 

［9］Miller AB，Hoogstraten B，Staquet M，et al.Reporting results of cancer treatment［J］.Cancer，1981，47(1)：207-214. 

［10］Eisenhauer EA，Therasse P，Bogaerts J，et al.New response evaluation criteria in solid tumours：revised RECIST guideline(version 1.1)［J］.Eur J Cancer，2009，45(2)：228-247. 

［11］Simmons C，Miller N，Geddie W，et al.Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? ［J］.Ann Oncol，2009，20(9)：1499-1504. 

［12］Tapia C，Savic S，Wagner U，et al.HER2 gene status in primary breast cancers and matched distant metastases［J］.Breast Cancer Res，2007，9(3)：R31. 

［13］Aktas B，Müller V，Tewes M，et al.Epub 2011 May 24.Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients［J］.Gynecol Oncol，2011，122(2)：356-360. 

［14］Wu X，Somlo G，Yu Y，et al.De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer［J］.J Transl Med，2012，10(1)：42［Epub ahead of print］

［15］杨国华，薛芳沁，陈晓耕.不同分子分型乳腺癌干细胞MDR1表达的研究［J］.南方医科大学学报，2012，32（11）：1636-1638. 

［16］韩冬艳，朱延波，蒋虹伟.CerbB2、ER、PR、Ki67在乳腺癌中的表达及其意义［J］.武警后勤学院学报（医学版），2012，21（6）：85-87. 

［17］于金明，袁双虎.肿瘤放疗的发展与挑战［J］.山东大学学报（医学版），2011，49（10）：48-50,66. 

［18］Groheux D，Giacchetti S，Espie M，et al.The yield of 18F-FDG PET/CT in patients with clinical stageⅡA，ⅡB，or ⅢA breast cancer：A prospective study［J］.J Nucl Med，2011，52(10)：1526-1534. 